Ireland - English - HPRA (Health Products Regulatory Authority)

b. braun medical limited - glucose monohydrate sodium chloride - solution for infusion - 37.5 %w/v

Canada - English - Health Canada

canadian poultry consultants ltd - vitamin a; vitamin d3; vitamin e; vitamin b12; folic acid; menadione; calcium d-pantothenate; nicotinic acid; vitamin b2; choline bitartrate; sodium chloride; sodium acetate; sodium diacetate; potassium chloride; magnesium chloride; calcium acetate - powder for solution - 3200000unit; 2500000unit; 3750unit; 6400mcg; 380mg; 1250mg; 8000mg; 16800mg; 3200mg; 14400mg; 694g; 89g; 18g; 36g; 18g; 18g - vitamin a 3200000unit; vitamin d3 2500000unit; vitamin e 3750unit; vitamin b12 6400mcg; folic acid 380mg; menadione 1250mg; calcium d-pantothenate 8000mg; nicotinic acid 16800mg; vitamin b2 3200mg; choline bitartrate 14400mg; sodium chloride 694g; sodium acetate 89g; sodium diacetate 18g; potassium chloride 36g; magnesium chloride 18g; calcium acetate 18g - poultry; poultry; poultry; poultry

Israel - English - Ministry of Health

padagis israel agencies ltd, israel - ascorbic acid; macrogols; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate anhydrous - powder for solution - potassium chloride 1.015 g; sodium ascorbate 5.9 g; macrogols 100 g; sodium chloride 2.691 g; sodium sulfate anhydrous 7.5 g; ascorbic acid 4.7 g - electrolytes in combination with other drugs - electrolytes in combination with other drugs - for bowel cleansing prior to any clinical procedures requiring a clean bowel e.g. bowel endoscopy or radiology.

United States - English - NLM (National Library of Medicine)

affordable pharmaceuticals, llc - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p), sodium sulfate anhydrous (unii: 36kcs0r750) (sodium cation - unii:lyr4m0nh37, sulfate ion - unii:7is9n8kpmg), sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - unii:lyr4m0nh37, bicarbonate ion - unii:hn1zra3q20), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q3 - polyethylene glycol 3350 236 g in 4 l - peg-3350 and electrolytes for oral solution is indicated for bowel cleansing prior to colonoscopy and barium enema x-ray examination in adults. peg-3350 and electrolytes for oral solution is contraindicated in the following conditions: - gastrointestinal (gi) obstruction [see warnings and precautions ( 5.6)] - bowel perforation [see warnings and precautions ( 5.6)] - toxic colitis or toxic megacolon - gastric retention - ileus - hypersensitivity to any component of peg-3350 and electrolytes for oral solution [see warnings and precautions ( 5.8)] animal reproduction studies have not been conducted with peg-3350 and electrolytes for oral solution. it is also not known whether peg-3350 and electrolytes for oral solution can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. peg-3350 and electrolytes for oral solution should be given to a pregnant woman only if clearly nee

United States - English - NLM (National Library of Medicine)

oceanside pharmaceuticals - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p), sodium sulfate (unii: 0ypr65r21j) (sodium sulfate anhydrous - unii:36kcs0r750), sodium chloride (unii: 451w47iq8x) (chloride ion - unii:q32zn48698), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - polyethylene glycol-3350, electrolytes, and ascorbate for oral solution is an osmotic laxative indicated for cleansing of the colon as a preparation for colonoscopy in adults. polyethylene glycol-3350, electrolytes, and ascorbate for oral solution is contraindicated in the following conditions: risk summary there are no available data on polyethylene glycol-3350, electrolytes, and ascorbate for oral solution in pregnant women to inform a drug-associated risk for adverse developmental outcomes. animal reproduction studies have not been conducted with polyethylene glycol-3350, electrolytes, and ascorbate for oral solution. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. risk summary the

Ireland - English - HPRA (Health Products Regulatory Authority)

b. braun melsungen ag - glucose monohydrate; soya bean oil; medium chain triglycerides; isoleucine; leucine; lysine monohydrate; methionine; phenylalanine; threonine; tryptophan; valine; arginine; histidine; alanine; aspartic acid; glutamic acid; glycine; proline; serine - emulsion for infusion - n/a - solutions for parenteral nutrition; combinations

Ireland - English - HPRA (Health Products Regulatory Authority)

b. braun melsungen ag - isoleucine; leucine ; lysine monohydrate; methionine; phenylalanine; threonine; tryptophan; valine; arginine ; histidine; alanine; aspartic acid; glutamic acid ; glycine; proline; serine; glucose monohydrate; triglycerides medium-chain ; soya bean oil, refined ph. eur.; omega-3-acid triglycerides - emulsion for infusion - 0 millilitre(s) - solutions for parenteral nutrition; combinations

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - leucine, quantity: 4.02 g/l; phenylalanine, quantity: 3.08 g/l; methionine, quantity: 2.2 g/l; lysine hydrochloride, quantity: 3.99 g/l (equivalent: lysine, qty 3.19 g/l); isoleucine, quantity: 3.3 g/l; valine, quantity: 3.19 g/l; histidine, quantity: 2.64 g/l; threonine, quantity: 2.31 g/l; tryptophan, quantity: 990 mg/l; alanine, quantity: 11.4 g/l; glycine, quantity: 5.66 g/l; arginine, quantity: 6.32 g/l; proline, quantity: 3.74 g/l; tyrosine, quantity: 220 mg/l; serine, quantity: 2.75 g/l; sodium aceta - injection, intravenous infusion - excipient ingredients: sodium metabisulfite; glacial acetic acid; water for injections - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - leucine, quantity: 7.3 g/l; phenylalanine, quantity: 5.6 g/l; methionine, quantity: 4 g/l; lysine hydrochloride, quantity: 7.24 g/l (equivalent: lysine, qty 5.8 g/l); isoleucine, quantity: 6 g/l; valine, quantity: 5.8 g/l; histidine, quantity: 4.8 g/l; threonine, quantity: 4.2 g/l; tryptophan, quantity: 1.8 g/l; alanine, quantity: 20.7 g/l; glycine, quantity: 10.3 g/l; arginine, quantity: 11.5 g/l; proline, quantity: 6.8 g/l; tyrosine, quantity: 400 mg/l; serine, quantity: 5 g/l; sodium acetate, quantity: 6 - injection, intravenous infusion - excipient ingredients: sodium metabisulfite; acetic acid; water for injections - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - leucine, quantity: 7.3 g/l; phenylalanine, quantity: 5.6 g/l; methionine, quantity: 4 g/l; lysine hydrochloride, quantity: 7.24 g/l (equivalent: lysine, qty 5.8 g/l); isoleucine, quantity: 6 g/l; valine, quantity: 5.8 g/l; histidine, quantity: 4.8 g/l; threonine, quantity: 4.2 g/l; tryptophan, quantity: 1.8 g/l; alanine, quantity: 20.7 g/l; glycine, quantity: 10.3 g/l; arginine, quantity: 11.5 g/l; proline, quantity: 6.8 g/l; tyrosine, quantity: 400 mg/l; serine, quantity: 5 g/l - injection, intravenous infusion - excipient ingredients: sodium metabisulfite; glacial acetic acid; water for injections - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)